Role of angiotensin II in coagulation and fibrinolysis

Nancy J. Brown, Douglas E. Vaughan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Activation of the renin-angiotensin system increases the risk of atherohrombotic events in hypertensive patients. This relationship may be explained by multiple mechanisms, including effects on platelet function and on fibrinolysis. There is substantial evidence that angiotensin-converting enzyme (ACE) inhibitors may exert antithrombotic effects by enhancing the bradykinin-dependent release of tissue plasminogen activator (t-PA) while reducing the angiotensin-dependent production of its natural inhibitor PAI- 1, thus improving vascular fibrinolytic balance. Recent studies suggest that angiotensin (II) type 1 (AT1) receptor antagonists inhibit the effects of prothrombotic prostanoids. The antithrombotic effects of agents that block the RAS may contribute to their vasculoprotective properties.

Original languageEnglish (US)
Pages (from-to)193-198
Number of pages6
JournalHeart Failure Reviews
Issue number3
StatePublished - 1999


  • ACE inhibition
  • Ang II Receptor blockade
  • Fibrinolysis
  • PAI-1
  • Platelet function
  • t-PA

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Role of angiotensin II in coagulation and fibrinolysis'. Together they form a unique fingerprint.

Cite this